Imatinib Mesylate 400mg | Brand: Glivec | 📷 medshopy.com/blood-cancer-medicine.html
London's Royal Marsden, University College Hospital, and King's College Hospital manage some of the UK's highest volumes of CML and GIST patients on long-term Imatinib therapy. For London patients seeking private supply outside NHS channels — including international patients receiving treatment at London's world-renowned private cancer hospitals — Imatib 400mg delivers identical clinical outcomes to brand Glivec at dramatically lower cost.
The discovery of Imatinib's remarkable efficacy in CML transformed the disease from a near-universally fatal leukaemia into a condition where most patients now achieve near-normal life expectancy. London's internationally diverse patient population includes many who travel specifically for cancer care, making affordable generic access critical for self-funding international patients.
Visit medshopy.com or WhatsApp +91 82650 41513 for London supply.
❓ How did Imatinib change the outlook for CML patients so dramatically?
Before Imatinib, CML was treated with interferon-alpha injections and hydroxyurea — which produced modest responses but rarely prevented progression to blast crisis and death, with 5-year survival rates around 30-40%. Imatinib, approved in 2001, targeted the specific BCR-ABL protein driving CML with unprecedented precision, producing complete cytogenetic remission in over 80% of patients — something almost unheard of in cancer medicine at the time. Today, CML patients on Imatinib have an estimated 90%+ 10-year survival rate, essentially matching the general population. This transformation made Imatinib the most celebrated example of targeted cancer therapy and the prototype for all subsequent precision oncology drugs.
